Skip to main content
Premium Trial:

Request an Annual Quote

HUPO President Says 2002 Will Be the Year of the Proteome

NEW YORK, Jan. 25 - Human Proteome Organization President Sam Hanash said he expects 2002 to be critical both for proteomics companies and for HUPO as the two try to prove they can live up to their potential.

"For groups and companies [that] declared one or two years ago that their goals are doing something big in proteomics, then I think by 2002 they should have had enough of a lead time to tell the world what it is that they have done," Hanash said in a recent interview.

He cited Myriad Genetics and Celera Genomics as two examples of companies that have promised much but so far delivered little. Celera, for example, has raised close to a billion dollars toward its proteomics efforts, Hanash added, and by the end of 2002 the company will have spent two years studying the proteome.

"Knowing that it took less than that to do the whole genome I would like to know how much they've been able to do with respect to the proteome," he said.

But Hanash indicated that the private sector's ability to fulfill its promises is not necessarily divorced from HUPO's fortunes. On the other hand, Hanash said the potential for the major players to fall short of their goals presents opportunities for his organization because a poor performance by a corporation could make collaborations with academics more attractive.

"The contrasting view is that no one platform will tackle it all, and this creates opportunities for community efforts," Hanash said.

In its first year, however, HUPO was unable to rally its members around a common scientific cause, and Hanash admitted that the organization will face pressure to prove that it can take on a leadership role.

"There has yet to be a formulation of what a major public initiative in proteomics would look like, be it a proteome project, or a multitude of proteome projects," he said. "So I think 2002 is going to be crucial with respect to sketching out what a major public proteomics initiative would look like."

Hanash said his other goals for HUPO during the year include holding its first annual congress and sponsoring training workshops. "HUPO would be expected to be definitely running as an established organization in 2002," he said.

HUPO's role in training scientists and graduate students in proteomics is especially important, Hanash said, because of the number of academic scientists who have migrated to industry over the last year.

"Maybe that will reach equilibrium in a year or so," he said, "but HUPO is very aware [of the need for training], and that's part of our mission."

 

This article originally appeared in ProteoMonitor.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more